Saitama Medical University International Medical Center - Dept of Otorhinolaryngology/ Head and Neck Surgery
Welcome,         Profile    Billing    Logout  
 9 Trials 
17 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Thariat, Juliette
NANORAY-312, NCT04892173 / 2021-002163-22: NBTXR3 With or Without Cetuximab in LA-HNSCC

Recruiting
3
500
Europe, Canada, Japan, US, RoW
NBTXR3, Functionalized hafnium oxide nanoparticles, Cetuximab, Erbitux, Radiation Therapy
Nanobiotix, Nanobiotix SA
Locally Advanced Head and Neck Squamous Cell Carcinoma, Aged
06/26
06/27
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated
3
166
Europe, Canada, Japan, US, RoW
Xevinapant (Debio 1143), IMRT, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
08/24
08/24
OPTIFLAP, NCT06798922: Flap Sparing in Postoperative Radiotherapy of Oral Cavity Cancers: a De-escalation Randomized Phase III Trial

Not yet recruiting
3
348
Europe
Standard post-operative radiotherapy without flap sparing (current practice), Post-operative radiotherapy with flap sparing
Centre Francois Baclesse
Oral Cavity Carcinoma, Flap, Radiotherapy, Adjuvant, Reconstructive Surgery After Carcinological Excision
03/31
03/34
PembroMetaRT, NCT04747054: Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers

Recruiting
3
102
Europe
Pembrolizumab, KEYTRUDA, Loco-regional radiotherapy, Chemotherapy
UNICANCER, GORTEC, National Cancer Institute, France
Squamous Cell Carcinoma of Head and Neck
10/25
10/29
Stereosarc, NCT03548428 / 2017-004239-35: Stereotaxic Body Irradiation of Oligometastase in Sarcoma

Recruiting
2
103
Europe
Atezolizumab, SBRT, High Dose Radiation
Centre Antoine Lacassagne, Centre Hospitalier Universitaire de Caen, Roche Pharma AG
Sarcoma, Radiosurgery
07/25
12/27
SinocaRT, NCT05943119: Phase II Study of Intensity Modulated Radiotherapy in Dose Painting for Sinus Carcinomas After Endoscopic Surgery

Recruiting
2
52
Europe
Radiotherapy in painting dose on histoscannographic mapping, Standard pan-sinusal Radiotherapy
Centre Francois Baclesse
Tumor, Solid
01/28
03/29
ORGAVADS, NCT04261192: Establishment of Squamous Cell Organoids of the Head and Neck to Assess Their Response to Innovative Therapies

Recruiting
N/A
120
Europe
Constitution of tumor and blood samples
Centre Francois Baclesse
Head and Neck Cancer
02/26
02/31
CYRAD, NCT05082961: Circulating Immunes Cells, Cytokines and Brain Radiotherapy

Recruiting
N/A
40
Europe
Collection of blood samples
Centre Francois Baclesse, Centre National de la Recherche Scientifique, France, Ligue contre le cancer, France, Fondation de France
Head and Neck Cancer
04/28
10/28
ETOILE, NCT02838602: Randomized Carbon Ions vs Standard Radiotherapy for Radioresistant Tumors

Recruiting
N/A
250
Europe
Carbon ions therapy, Advanced external radiotherapy by Xrays or protons
Hospices Civils de Lyon
Malignant Tumors as Chordoma, Adenoid Cystic Carcinoma and Sarcoma
12/26
12/26
REFCORbirth, NCT03738267: Study on the Occurrence of Head and Neck Cancers During Pregnancy

Active, not recruiting
N/A
14
Europe
Centre Francois Baclesse, French scientific group REFCOR
Head and Neck Cancer, Pregnancy Related
05/27
05/27
HARMONIC-RT, NCT04746729: Health Effects of CArdiac FluoRoscopy and MOderN RadIotherapy in PediatriCs - Radiotherapy

Recruiting
N/A
2670
Europe
No intervention
Institut National de la Santé Et de la Recherche Médicale, France, Barcelona Institute for Global Health, The West German Proton Therapy Centre, Essen, Gustave Roussy, Cancer Campus, Grand Paris, Centre Francois Baclesse, KU Leuven, University of Aarhus, Princess Maxima Center for Pediatric Oncology, University Medical Center Groningen, Stockholm University, National Research Council, Institute of Clinical Physiology, Italy, University of Zurich, Commissariat A L'energie Atomique, Luxembourg Institute of Science and Technology, University Hospital, Essen, Aarhus University Hospital
Neoplasms
09/40
09/40
Yamazaki, Tomoko
JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Recruiting
3
864
Europe, Canada, Japan, US, RoW
Dostarlimab, Placebo
GlaxoSmithKline
Neoplasms, Head and Neck
05/28
07/29
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated
3
166
Europe, Canada, Japan, US, RoW
Xevinapant (Debio 1143), IMRT, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
08/24
08/24
NCT06062420: A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

Recruiting
2
360
Europe, Canada, Japan, US, RoW
Dostarlimab, Belrestotug, Nelistotug, GSK4381562
GlaxoSmithKline, iTeos Therapeutics
Neoplasms, Head and Neck
05/27
05/27
Vulquin, Noemie
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated
3
166
Europe, Canada, Japan, US, RoW
Xevinapant (Debio 1143), IMRT, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
08/24
08/24
Bosset, Matthieu
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated
3
166
Europe, Canada, Japan, US, RoW
Xevinapant (Debio 1143), IMRT, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
08/24
08/24
PembroMetaRT, NCT04747054: Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers

Recruiting
3
102
Europe
Pembrolizumab, KEYTRUDA, Loco-regional radiotherapy, Chemotherapy
UNICANCER, GORTEC, National Cancer Institute, France
Squamous Cell Carcinoma of Head and Neck
10/25
10/29

Download Options